Using prebiotics to improve kidney transplant outcomes
Prebiotic Therapy to Improve Outcomes of Renal Transplant
This study is testing if a special prebiotic can help improve kidney transplant success and reduce side effects for people who have just received a kidney.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 1 site (London, Ontario) |
| Trial ID | NCT04428190 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates the effects of human milk oligosaccharide (HMO) prebiotic on kidney transplant outcomes in a randomized, double-blind, placebo-controlled design involving approximately 60 patients. Participants will receive either HMO or a placebo for 12 weeks following their kidney transplant, with follow-up assessments continuing for an additional 3 months. The study aims to determine if HMO can reduce delayed graft function and mitigate side effects from immunosuppressive therapy, ultimately improving the longevity and function of transplanted kidneys.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and over who are undergoing a kidney transplant.
Not a fit: Patients under 18, those with certain gastrointestinal conditions, or those currently using probiotics or prebiotics may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance kidney transplant outcomes and improve the quality of life for patients.
How similar studies have performed: While the use of prebiotics in this context is relatively novel, other studies have shown promising results with similar approaches in improving transplant outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age and over receiving a kidney transplant. Exclusion Criteria: * Under 18 years of age * Inability to give consent * Usage of probiotics or other prebiotics. * Have had carcinomas during the last 5 years * Bowel surgery * Crohn ́s disease and other conditions.
Where this trial is running
London, Ontario
- London Health Sciences Centre — London, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Alp Sener, MD — London Health Sciences Centre
- Study coordinator: Mounirah May
- Email: mounirah.may@lhsc.on.ca
- Phone: 519-685-8500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.